Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) Sees Large Growth in Short Interest

Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 5,039 shares, an increase of 68.9% from the September 30th total of 2,984 shares. Based on an average daily trading volume, of 4,298 shares, the days-to-cover ratio is currently 1.2 days.

Insider Transactions at Leverage Shares 2X Long FIX Daily ETF

In related news, CFO Lee Kalowski sold 3,972 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the transaction, the chief financial officer directly owned 138,471 shares in the company, valued at $2,293,079.76. This represents a 2.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Pope Morrison sold 3,221 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $8.32, for a total transaction of $26,798.72. Following the completion of the transaction, the chief executive officer directly owned 340,038 shares in the company, valued at approximately $2,829,116.16. The trade was a 0.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 22,054 shares of company stock worth $320,397 in the last quarter.

Leverage Shares 2X Long FIX Daily ETF Price Performance

Shares of Leverage Shares 2X Long FIX Daily ETF stock opened at $6.35 on Tuesday. The company’s fifty day simple moving average is $11.48. Leverage Shares 2X Long FIX Daily ETF has a 52 week low of $5.61 and a 52 week high of $15.92.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.